BioCentury | Jan 21, 2016
Finance

Italy's velocity factor

...worked together previously to build successful biotech companies. Most recently, the pair partnered to develop Ethical Oncology Science S.p.A....
BioCentury | Nov 23, 2015
Finance

Turbo-charging Italian biotech

...To mentor them, Sofinnova brought back the team that ran its most successful Italian investment, Ethical Oncology Science S.p.A....
BioCentury | Jan 24, 2015
Financial News

Gene therapy newco Genenta raises EUR 6.2M toward series A

...McKinsey & Co. director, is a director at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA). Camboni founded Ethical Oncology Science S.p.A....
BioCentury | Jul 21, 2014
Clinical News

Lucitanib: Additional Phase II data

...of lucitanib in advanced breast cancer. Last November, Clovis gained lucitanib through its acquisition of Ethical Oncology Science S.p.A....
BioCentury | Dec 9, 2013
Financial News

Clovis financial update

...I, Principia SGR and individual investors. The investors acquired the shares through Clovis' acquisition of Ethical Oncology Science...
BioCentury | Nov 25, 2013
Company News

Clovis, Ethical Oncology Science deal

...Clovis acquired Ethical Oncology Science for $200 million up front - including $10 million in cash and about...
...trial of lucitanib in patients with advanced breast cancer. Clovis Oncology Inc. (NASDAQ:CLVS), Boulder, Colo. Ethical Oncology Science S.p.A....
BioCentury | Nov 25, 2013
Finance

It pays to be Ethical

Ethical Oncology Science S.p.A. 's investors are in line for at least 7x on their money based solely on the $200 million in upfront cash and stock that Clovis Oncology Inc. (NASDAQ:CLVS) is paying for...
BioCentury | Nov 20, 2013
Company News

Clovis acquires EOS

...Clovis Oncology Inc. (NASDAQ:CLVS) acquired Ethical Oncology Science S.p.A. (Milan, Italy) for $200 million up front -- including $10...
BioCentury | Oct 15, 2012
Strategy

At home with Servier

...attack Dealing with cancer Partner Description Financial details Target Status at time of deal Date Ethical Oncology Science S.p.A....
BioCentury | Oct 2, 2012
Company News

Servier, EOS in cancer deal

Ethical Oncology Science S.p.A. (Milan, Italy) and Servier (Neuilly-sur-Seine, France) partnered to co-develop the Italian company's cancer product called E-3810 . The small molecule inhibitor of fibroblast growth factor (FGF) receptor 1 ( FGFR1 ) and VEGF is...
Items per page:
1 - 10 of 10
BioCentury | Jan 21, 2016
Finance

Italy's velocity factor

...worked together previously to build successful biotech companies. Most recently, the pair partnered to develop Ethical Oncology Science S.p.A....
BioCentury | Nov 23, 2015
Finance

Turbo-charging Italian biotech

...To mentor them, Sofinnova brought back the team that ran its most successful Italian investment, Ethical Oncology Science S.p.A....
BioCentury | Jan 24, 2015
Financial News

Gene therapy newco Genenta raises EUR 6.2M toward series A

...McKinsey & Co. director, is a director at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA). Camboni founded Ethical Oncology Science S.p.A....
BioCentury | Jul 21, 2014
Clinical News

Lucitanib: Additional Phase II data

...of lucitanib in advanced breast cancer. Last November, Clovis gained lucitanib through its acquisition of Ethical Oncology Science S.p.A....
BioCentury | Dec 9, 2013
Financial News

Clovis financial update

...I, Principia SGR and individual investors. The investors acquired the shares through Clovis' acquisition of Ethical Oncology Science...
BioCentury | Nov 25, 2013
Company News

Clovis, Ethical Oncology Science deal

...Clovis acquired Ethical Oncology Science for $200 million up front - including $10 million in cash and about...
...trial of lucitanib in patients with advanced breast cancer. Clovis Oncology Inc. (NASDAQ:CLVS), Boulder, Colo. Ethical Oncology Science S.p.A....
BioCentury | Nov 25, 2013
Finance

It pays to be Ethical

Ethical Oncology Science S.p.A. 's investors are in line for at least 7x on their money based solely on the $200 million in upfront cash and stock that Clovis Oncology Inc. (NASDAQ:CLVS) is paying for...
BioCentury | Nov 20, 2013
Company News

Clovis acquires EOS

...Clovis Oncology Inc. (NASDAQ:CLVS) acquired Ethical Oncology Science S.p.A. (Milan, Italy) for $200 million up front -- including $10...
BioCentury | Oct 15, 2012
Strategy

At home with Servier

...attack Dealing with cancer Partner Description Financial details Target Status at time of deal Date Ethical Oncology Science S.p.A....
BioCentury | Oct 2, 2012
Company News

Servier, EOS in cancer deal

Ethical Oncology Science S.p.A. (Milan, Italy) and Servier (Neuilly-sur-Seine, France) partnered to co-develop the Italian company's cancer product called E-3810 . The small molecule inhibitor of fibroblast growth factor (FGF) receptor 1 ( FGFR1 ) and VEGF is...
Items per page:
1 - 10 of 10